Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Monica E. Wielgos"'
Autor:
Eddy S. Yang, Susan E. Nozell, Albert F. LoBuglio, Rachel Schiff, C. Kent Osborne, Francisco J. Esteva, Andres Forero, Ling Zeng, Tiffiny S. Cooper, Rajani Rajbhandari, Zhuo Zhang, Monica E. Wielgos
Supplemental Methods and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c5a8b57cc45d1d222f8d418e134855
https://doi.org/10.1158/1535-7163.22505158
https://doi.org/10.1158/1535-7163.22505158
Autor:
Eddy S. Yang, Susan Nozell, Shi Wei, Tiffiny S. Cooper, Rajani Rajbhandari, Monica E. Wielgos
Expression of miR-223 is not significantly altered between HER2- and HER2+ breast cancer cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618b0cf9bd4bcd0443fd3c7de1170c3e
https://doi.org/10.1158/1541-7786.22511889
https://doi.org/10.1158/1541-7786.22511889
Autor:
Eddy S. Yang, Susan E. Nozell, Albert F. LoBuglio, Rachel Schiff, C. Kent Osborne, Francisco J. Esteva, Andres Forero, Ling Zeng, Tiffiny S. Cooper, Rajani Rajbhandari, Zhuo Zhang, Monica E. Wielgos
SFigure1: HER2+ breast cancer cells are sensitive to nirparib SFigure2: HER2+ breast cancer microtumors are sensitive to ABT-888 SFigure3: (A) ABT-888 reduces PAR levels in HER2+ xenograft models. (B) ABT-888 did not cause weight loss in mice SFigure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304cc460640481e9f8fa3bf07cd6c7b4
https://doi.org/10.1158/1535-7163.22505161.v1
https://doi.org/10.1158/1535-7163.22505161.v1
Autor:
Eddy S. Yang, Susan Nozell, Shi Wei, Tiffiny S. Cooper, Rajani Rajbhandari, Monica E. Wielgos
HER2+ breast tumors have been shown to express elevated levels of PARP1 protein. Yet, the mechanism by which PARP1 is upregulated in HER2+ breast cancer is unknown. Here, knockdown of HER2 (ERBB2) in HER2+ breast cancer cells resulted in a reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::239025a1506a95b5944b98f2ef9e059f
https://doi.org/10.1158/1541-7786.c.6540069.v1
https://doi.org/10.1158/1541-7786.c.6540069.v1
Autor:
Eddy S. Yang, Susan Nozell, Shi Wei, Tiffiny S. Cooper, Rajani Rajbhandari, Monica E. Wielgos
Supplemental Data Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5c18c15deecd1cfe4db97c5e8492b5
https://doi.org/10.1158/1541-7786.22511898
https://doi.org/10.1158/1541-7786.22511898
Autor:
Rachel Schiff, Francisco J. Esteva, Eddy S. Yang, Albert F. LoBuglio, Monica E. Wielgos, Andres Forero, Zhuo Zhang, C. Kent Osborne, Susan Nozell, Ling Zeng, Tiffiny S. Cooper, Rajani Rajbhandari
HER2-targeted therapies, such as trastuzumab, have increased the survival rates of HER2+ breast cancer patients. However, despite these therapies, many tumors eventually develop resistance to these therapies. Our lab previously reported an unexpected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1898c1d3948273c9be8e180c7a8f807
https://europepmc.org/articles/PMC5932278/
https://europepmc.org/articles/PMC5932278/
Publikováno v:
Cancer Research. 79:3970-3970
Background: Currently, there are multiple ongoing clinical trials testing the efficacy of various poly (ADP-ribose) polymerase (PARP) inhibitors in combination with immune checkpoint blockade across many cancer types. However, there is no rationale a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a60da856f3b5a666d38da4c5ff1da99
https://doi.org/10.1158/1538-7445.am2019-3970
https://doi.org/10.1158/1538-7445.am2019-3970
Autor:
Douglas A. Levine, Paulina Cybulska, Michelle Firlit, Petar Jelinic, Elke Van Oudenhove, Jay R. Patibandla, Monica E. Wielgos
Publikováno v:
Cancer Research. 78:335-335
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer with low 5-year survival rates. Inhibitors of poly (ADP-ribose) polymerase (PARP) are promising novel agents that uniquely target HGSOCs with DNA repair deficien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d848711fc24a91c3c96d81ca29c4b75
https://doi.org/10.1158/1538-7445.am2018-335
https://doi.org/10.1158/1538-7445.am2018-335
Autor:
Ronald D. Alvarez, Monica E. Wielgos, Eddy S. Yang, Panagiotis A. Konstantinopoulos, Zachary C. Dobbin, Charles N. Landen, Somaira Nowsheen, Ashwini A. Katre, Monjri Shah
BRCA-positive ovarian cancer patients derive benefit PARP inhibitors. Approximately 50% of ovarian cancer tumors have homologous recombination (HR) deficiencies and are therefore "BRCA-like," possibly rendering them sensitive to PARP inhibition. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141bf961fcce30583023cf0d72c41e07
https://europepmc.org/articles/PMC4221419/
https://europepmc.org/articles/PMC4221419/
Autor:
Monica E. Wielgos, Eddy S. Yang
Publikováno v:
Pharmaceutical patent analyst. 2(6)
Poly (ADP-ribose) polymerases (PARP) are a family of enzymes that play a very important role in preserving the integrity of the genome. Recently, PARP inhibitors have been shown to enhance the therapeutic ratio in cancer patients due to their specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06bd266acc86a1ce06b8927ae2399d3
https://pubmed.ncbi.nlm.nih.gov/24237241
https://pubmed.ncbi.nlm.nih.gov/24237241